申请人:SMITHKLINE BEECHAM CORP
公开号:WO2002039954A2
公开(公告)日:2002-05-23
The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.